Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers

Altered Histology Provides a Positive Clinical Signal in the Bronchial Epithelium

(2011) E. Szabo   Cancer Prevention Research

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

(2011) R. L. Keith et al.   Cancer Prevention Research

Lung Cancer Chemoprevention with Celecoxib in Former Smokers

(2011) Jenny T. Mao et al.   Cancer Prevention Research

Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules

(2010) A Körner et al.   BRITISH JOURNAL OF CANCER

Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers

(2010) E. S. Kim et al.   Cancer Prevention Research

Assessing Efficacy in Early-Phase Cancer Prevention Clinical Trials: The Case of Ki-67 in the Lung

(2010) E. Szabo   Cancer Prevention Research

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

(2010) Alberto Chiappori et al.   Journal of Thoracic Oncology

Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer

(2008) Yun Oh et al.   JOURNAL OF CLINICAL ONCOLOGY